Based on current evidence, there’s no urgent need for the administration of booster doses of vaccines to completely vaccinated individuals within the general population, consistent…
The U.S. Food and Drug Administration today approved Byooviz (ranibizumab-nuna) because the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases…
As schools round the country are re-opening for in-person learning and families are returning to their busy academic year schedules, we all know many parents…
The following quote is attributed to Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research “The opioid crisis continues to evolve…
Approval Based on HAUSER-RCT Study Demonstrating a Significant Reduction in LDL-C Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha®…
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with coronary failure with preserved…
VUMERITY may be a next-generation oral fumarate with a well-characterized efficacy and safety profileData from the Phase 3 EVOLVE-MS-2 study have demonstrated that treatment with…